News | September 09, 2014

Tryton Medical Completes $20 Million Equity Financing For U.S. Approval

September 9, 2014 — Tryton Medical Inc. announced an initial closing of an aggregate $20 million private equity financing. Participating in this financing were existing investors RiverVest Venture Partners and 3x5 Special Opportunity Fund, joined by new investor Canepa Advanced Healthcare Fund and an unnamed investor. Alejandro Sanchez from Canepa U.S., which serves as investment advisor to Canepa Advanced Healthcare Fund, will be joining the Tryton Medical board of directors. Tryton is a developer of stents designed to treat coronary bifurcation lesions.

"The company will use these proceeds to complete enrollment in the Tryton IDE Extended Access Registry, to support our U.S. Food and Drug Administration (FDA) submission, and to develop the left main market opportunity with the CE-approved left main stent indication for our Tryton side branch stent," said Shawn P. McCarthy, president and CEO of Tryton Medical. "Tryton Medical’s differentiated technology addresses the challenges of bifurcation lesions, which affect nearly one-third of patients undergoing a PCI [percutaneous coronary intervention] procedure. The Tryton side branch stent has now been used to treat more than 10,000 patients around the world, and we're positioned to be the first and only coronary stent approved for use in treating bifurcation lesions in the United States."

The Tryton side branch stent is commercially available in multiple countries within Europe, Middle East and Africa; investigational in the United States; and unavailable in Japan. Coronary artery disease often results in the buildup of plaque at the site of a bifurcation, where one artery branches from another. Current approaches to treating these lesions are time consuming and technically difficult. As a result, the side branch is often left unstented, leaving it vulnerable to higher rates of restenosis. Left main disease, an accumulation of plaque that narrows the base of the coronary tree, is a persistent challenge in interventional cardiology, as more than 75 percent of left main lesions are bifurcation lesions.

For more information:

Related Content

Videos | Cath Lab | July 15, 2020
Richard Botto, CVT, RCSA, chief cardiovascular technologist, division of cardiology, cardiac cath lab, offers an over
Videos | Cath Lab | July 13, 2020
The Vieussens’ arterial ring (VAR) is a connection between the conus artery and the left anterior descending (LAD) co
News | Cath Lab | July 06, 2020
July 6, 2020 — Black patients who undergo percutaneous coronary intervention (PCI) are at an increased risk for major
TCT cancels in-person meeting and goes virtual due to COVID-19
News | Cath Lab | May 27, 2020
May 27, 2020 — To ensure the health and safety of all attendees due to the ongoing COVID-19 (SARS-CoV-2) pandemic, th
Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, or nil per os (NPO), as there are no current standardized fasting protocols, but the CHOWNOW study found patients do not need to fast and will have similar outcomes. #SCAI2020
Feature | Cath Lab | May 18, 2020
May 18, 2020 – Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, o
Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiography and Interventions (SCAI) and chief, Division of Cardiovascular Medicine at UC San Diego Medical Center,
Podcast | Cath Lab | May 13, 2020
This podcast is an interview with Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiograp
Nuance Communications Inc. introduced Nuance Cardiovascular CAPD, a new computer-assisted physician documentation (CAPD) solution designed to help cardiologists improve the quality of complex documentation and the accuracy of reimbursement for cardiac catheterization procedures. The Nuance Cardiovascular CAPD solution is available through a partnership with ZHealth for this solution, which is based on patented algorithms built with ZHealth’s interventional documentation and coding expertise.
News | Cath Lab | January 31, 2020
January 29, 2020 – Nuance Communications Inc.